SCHEMBL1154874

SCHEMBL1154874

Oc1nccc2cc[nH]c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.43
AXL P30530 2/20 0.38
NUDT1 P36639 2/20 0.38
AHR P35869 1/20 0.38
KEAP1 Q14145 1/20 0.37
PDPK1 O15530 1/20 0.36
RIPK1 Q13546 2/20 0.35
TNF P01375 1/20 0.35
BRD4 O60885 1/20 0.33
TAF1 P21675 1/20 0.33
BRPF1 P55201 1/20 0.33
CREBBP Q92793 1/20 0.33
CECR2 Q9BXF3 1/20 0.33
BRD9 Q9H8M2 1/20 0.33
TYR P14679 1/20 0.33
USP2 O75604 1/20 0.33
GAA P10253 1/20 0.33
ALOX15 P16050 1/20 0.33
RAD51 Q06609 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30678614 1.00 GRM5 (0.43) GRM5AXLNUDT1AHRKEAP1
SCHEMBL23233865 0.76 GRM5 (0.41) GRM5AXLNUDT1AHRKEAP1
SCHEMBL9942590 0.76 AHR (0.43) GRM5AXLNUDT1AHRKEAP1
SCHEMBL401223 0.74 NOS3 (0.42) GRM5AXLNUDT1AHRKEAP1
SCHEMBL30781502 0.74 TNF (0.44) GRM5AXLNUDT1AHRKEAP1
SCHEMBL762091 0.74 DYRK1A (0.48) GRM5AXLNUDT1AHRKEAP1
SCHEMBL2633337 0.74 GRM5 (0.43) GRM5AXLNUDT1AHRKEAP1
SCHEMBL30122523 0.74 DYRK1A (0.48) GRM5AXLNUDT1AHRKEAP1
SCHEMBL652414 0.74 GRM5 (0.40) GRM5AXLNUDT1AHRKEAP1
SCHEMBL3276660 0.72 GRM5 (0.56) GRM5KEAP1PDPK1ALOX15NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013170-B1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2012-06-27 EP disclosed
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. 2011-02-24 US disclosed
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. 2011-02-24 US disclosed
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. 2011-02-24 US disclosed
WO-2009091939-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. (US) 2009-07-23 WO disclosed
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
EP-2013170-A1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS Brystol-Myers Squibb Company (US) 2009-01-14 EP disclosed
WO-2007127731-A1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-08 WO disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents MAVS, MTAP, SAMHD1 GRM5 898/4885AXL 4380/4885NUDT1 217/4885
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS IGF1R, IGFBP3, INSR GRM5 838/4885AXL 1837/4885NUDT1 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.